9 Meters Biopharma Inc
OTC:NMTRQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ikegps Group Ltd
NZX:IKE
|
NZ |
|
Hakuyosha Co Ltd
TSE:9731
|
JP |
|
G
|
Gold Hydrogen Ltd
ASX:GHY
|
AU |
|
Hyve Group PLC
LSE:HYVE
|
UK |
|
S
|
Sun International Ltd
XBER:RY1B
|
ZA |
|
M
|
Mediplantex National Pharmaceutical JSC
VN:MED
|
VN |
|
MTU Aero Engines AG
XETRA:MTX
|
DE |
|
Pharmacielo Ltd
XTSX:PCLO
|
CA |
|
Atco Ltd
TSX:ACO.Y
|
CA |
|
Huafa Property Services Group Co Ltd
HKEX:982
|
HK |
9 Meters Biopharma Inc
Total Receivables
9 Meters Biopharma Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
9 Meters Biopharma Inc
OTC:NMTRQ
|
Total Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Receivables
$17.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Receivables
$14.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
11%
|
CAGR 10-Years
13%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Receivables
$15.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
15%
|
CAGR 10-Years
7%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Receivables
$12.7B
|
CAGR 3-Years
8%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Receivables
$20.2B
|
CAGR 3-Years
33%
|
CAGR 5-Years
24%
|
CAGR 10-Years
17%
|
|
9 Meters Biopharma Inc
Glance View
9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on rare and unmet needs in gastroenterology. The company is headquartered in Raleigh, North Carolina and currently employs 21 full-time employees. The company went IPO on 2016-07-08. The firm is focused on developing treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs. Its pipeline includes Vurolenatide, Larazotide, NM-102, NM-003, NM-136 and NM-004. Vurolenatide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that combines exenatide with an extended half-life technology for treatment of short bowel syndrome (SBS). Larazotide is an 8-amino acid peptide formulated into an orally administered capsule for treatment of celiac disease. NM-102 is a small molecule peptide, is being developed as a potential microbiome modulator and is undergoing an indication selection process. NM-003 is a long-acting GLP-2 receptor agonist, for prevention of acute graft versus host disease. NM-004 is a double-cleaved mesalamine with an immunomodulator for pediatric ulcerative colitis.
